The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer. Commentary re: J. Kwong et al., Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin. Cancer Res., 8: 131-137, 2002, and H-Z. Zou et al., Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin. Cancer Res., 8: 188-191, 2002.
Widschwendter
Martin
M
University of Southern California/Norris Comprehensive Cancer Center, Department of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, Los Angeles, California 90089-9181, USA. Martin.Widschwendter@uibk.ac.at
Jones
Peter A
PA
D002869:Chromosome Aberrations; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000235:genetics; D019175:DNA Methylation; D004273:DNA, Neoplasm / Q000097:blood / Q000235:genetics*; D015870:Gene Expression; D020868:Gene Silencing; D006801:Humans; D018895:Microsatellite Repeats; D009154:Mutation; D009369:Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality; D011237:Predictive Value of Tests; D011379:Prognosis; D011401:Promoter Regions, Genetic; D015996:Survival Rate
D019941:Cyclin-Dependent Kinase Inhibitor p16; D004273:DNA, Neoplasm